Here is a report of a preliminary study done on effects of genetic influence on sertaline treatment for alzheimers.

Team@CMHF

Objective: To assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD).
Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met).
We utilized data from the Depression in Alzheimer’s Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Results. No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks.
Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression.

Ref: http://www.docguide.com/sertraline-treatment-depression-alzheimer-disease-genetic-influences?hash=80445d1a&eid=24262&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2